platelet plug
Summary
The platelet plug is the initial hemostatic response to vascular injury, formed via platelet adhesion, activation, and aggregation at the site of endothelial damage. It constitutes primary hemostasis, occurring within seconds to minutes, and precedes the secondary hemostasis (coagulation cascade) that stabilizes the clot with fibrin.
Detail
Platelet plug formation occurs in four key steps: (1) Adhesion - upon endothelial injury, exposed subendothelial collagen binds von Willebrand factor (vWF), which is released from Weibel-Palade bodies of endothelial cells and alpha granules of platelets; platelets adhere to vWF via glycoprotein Ib (GpIb) receptors; (2) Activation - platelets change shape (from discoid to spiculated), release granule contents (ADP, thromboxane A2, serotonin, calcium) which recruit and activate additional platelets, and express GpIIb/IIIa receptors on their surface; (3) Aggregation - fibrinogen crosslinks adjacent platelets via GpIIb/IIIa receptors, forming the platelet aggregate; (4) Stabilization - the platelet plug is reinforced by the coagulation cascade producing fibrin (secondary hemostasis), converting the loose plug into a stable clot.
Clinical significance: Defects in this pathway cause distinct bleeding patterns. Disorders of primary hemostasis (platelet plug formation) typically present with mucocutaneous bleeding - petechiae, purpura, epistaxis, gingival bleeding, and menorrhagia - as opposed to the deep tissue/joint bleeding seen in coagulation factor deficiencies (secondary hemostasis, e.g., hemophilia).
Key disorders: Bernard-Soulier syndrome (GpIb deficiency, impaired adhesion), Glanzmann thrombasthenia (GpIIb/IIIa deficiency, impaired aggregation), von Willebrand disease (most common inherited bleeding disorder, affects both adhesion and factor VIII stability), and thrombocytopenia (quantitative platelet deficiency from various causes: ITP, TTP, DIC, bone marrow suppression).
Pharmacology correlations: Aspirin irreversibly inhibits COX-1, blocking thromboxane A2 synthesis and thus platelet activation/aggregation. Clopidogrel/ticagrelor block ADP receptors (P2Y12) on platelets. GpIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) directly block the final common aggregation step. These drugs are tested frequently regarding their mechanism and use in cardiovascular disease (e.g., post-MI, stent placement).
Laboratory correlation: Bleeding time and platelet function assays (e.g., PFA-100) assess primary hemostasis/platelet plug formation, while PT/PTT assess the secondary coagulation cascade.
Sources
- First Aid for the USMLE Step 1
- Robbins Basic Pathology
- Guyton and Hall Textbook of Medical Physiology
- Pathoma - Fundamentals of Pathology (Husain Sattar)
Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.